iSTantibody SIGNED
An innovative & seamless approach for the mass spectrometry analysis of monoclonal antibodies
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0iSTantibody project word cloud
Explore the words cloud of the iSTantibody project. It provides you a very rough idea of what is the project "iSTantibody" about.
Project "iSTantibody" data sheet
The following table provides information about the project.
| Coordinator |
PREOMICS GMBH
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-05-01 to 2019-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | PREOMICS GMBH | DE (PLANEGG MARTINSRIED) | coordinator | 50˙000.00 |
Map
Project objective
Therapeutic monoclonal antibodies (mAbs) are innovative therapeutic tools that are currently drawing the attention of biopharma companies for their effectiveness against a broad panel of diseases. To guarantee safety for patients, tight control over the purity of mAbs preparations is crucial. The presence of contaminants in mAbs preparations can be assessed using mass spectrometry (MS), a technique characterised by remarkable sensitivity, but which requires a time-consuming, complicated and poorly reproducible sample preparation. Notably, at today’s date, this process cannot be automated or multiplexed: it has to be performed by highly skilled scientific staff, and - importantly - it cannot be easily “plugged in” the streamlined production approaches of pharma companies. PreOmics is a young German company seeking to revolutionise the MS proteomics market with its proprietary technology portfolio. Through the iSTantibody project, PreOmics translates its patented iST technology in the context of mAbs MS analysis and tackles the current pitfalls of mAbs sample preparation. Its final goal consists of a kit to simplify and shorten MS sample preparation by > 95% compared to standard protocols, eliminating the need for skilled scientists and allowing MS sample purification on automated liquid handling platforms. The advantages for potential customers are manifold – notably, significantly reduced costs, and the consequent possibility to free resources for mAbs development. The target sector of iSTantibody is the ever-growing market for MS sample preparation consumables, which is forecasted to reach a volume of € 1.3 billion worldwide in 2022, at a CAGR of 12%. The benefit of the iSTantibody project will produce remarkable benefits for PreOmics, both in terms of increased revenues ( € 15.3 million in 2026), employability (creation of 13 jobs) and innovation potential, opening new market perspectives and allowing PreOmics to seize more opportunities in the years ahead.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ISTANTIBODY" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ISTANTIBODY" are provided by the European Opendata Portal: CORDIS opendata.